Zacks Research Has Negative Estimate for Masimo Q3 Earnings

Masimo Co. (NASDAQ:MASI) – Equities researchers at Zacks Research dropped their Q3 2025 earnings estimates for Masimo in a note issued to investors on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical equipment provider will earn $1.07 per share for the quarter, down from their previous estimate of $1.15. The consensus estimate for Masimo’s current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo’s Q1 2026 earnings at $1.09 EPS and Q2 2026 earnings at $1.17 EPS.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share.

Several other research analysts also recently commented on MASI. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company raised their target price on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Piper Sandler boosted their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and an average price target of $167.00.

Masimo Stock Performance

Shares of Masimo stock opened at $170.89 on Thursday. The company has a market capitalization of $9.15 billion, a PE ratio of 117.86 and a beta of 0.97. Masimo has a 52 week low of $91.60 and a 52 week high of $178.27. The stock’s fifty day moving average is $148.22 and its two-hundred day moving average is $129.32. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Institutional Trading of Masimo

Several institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC grew its position in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 573 shares during the period. Tidal Investments LLC grew its holdings in Masimo by 14.1% in the first quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 269 shares during the period. Farallon Capital Management LLC increased its position in shares of Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after buying an additional 177,914 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the period. Finally, Juncture Wealth Strategies LLC lifted its position in shares of Masimo by 294.3% during the 2nd quarter. Juncture Wealth Strategies LLC now owns 7,992 shares of the medical equipment provider’s stock valued at $1,007,000 after buying an additional 5,965 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.